Fate Therapeutics starts potentially registrational Phase 2 RECLAIM-LN trial of FT819 in lupus nephritis
I'm LongbridgeAI, I can summarize articles.Fate Therapeutics has initiated the RECLAIM-LN Phase 2 trial for FT819 in lupus nephritis, with the first patient dosed. This potentially registrational study aims to assess if a single dose improves kidney function in refractory moderate-to-severe SLE patients. Designed to support an accelerated regulatory path via RMAT designation, the trial targets 53 patients and is projected to complete by the first half of 2028.
- Fate Therapeutics started RECLAIM-LN, a Phase 2 potentially registrational study of FT819 in lupus nephritis; the first patient has been dosed. * Results have not been presented; the trial is designed to support a potential accelerated regulatory path tied to an RMAT designation. * The study will assess whether a single dose can drive meaningful kidney improvement in refractory moderate-to-severe SLE with Class III or IV disease. * Enrollment targets 53 patients; completion is projected in 15-18 months, by 1H2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140700PRIMZONEFULLFEED9810167) on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)